



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

PI5P4Ks-IN-2

Cat. No.:	HY-153526		
CAS No.:	2766854-03-7		
Molecular Formula:	C ₂₂ H ₂₃ N ₅		
Molecular Weight:	357.45		
Target:	PI5P4K		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (349.70 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.7976 mL	13.9880 mL	27.9759 mL
5 mM	0.5595 mL	2.7976 mL	5.5952 mL
10 mM	0.2798 mL	1.3988 mL	2.7976 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PI5P4Ks-IN-2 is a inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4K γ). PI5P4Ks-IN-2 targets to PI5P4K isoforms with pIC₅₀ values of <4.3 (PI5P4K α), <4.6 (PI5P4K β), 6.2 (PI5P4K γ), 0.32 (PI5P4K γ +), respectively^[1].

IC₅₀ & Target

PI5P4K^[1]

In Vitro

PI5P4Ks-IN-2 (compound 40) (10 μ M) shows selectivity against a panel of 140 protein kinases and 15 lipid kinases, and binds to PI5P4K γ -WT (K_i=68 nM) or PI5P4K β (K_i>30,000 nM)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Boffey HK, et al. Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode. J Med Chem. 2022 Feb 24;65(4):3359-3370.

[2]. Boffey HK, et al. Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode. J Med Chem. 2022 Feb 24;65(4):3359-3370.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA